Author/Authors :
Falorni، نويسنده , , Alberto and Chen، نويسنده , , Shu and Zanchetta، نويسنده , , Renato and Yu، نويسنده , , Liping and Tiberti، نويسنده , , Claudio and Bacosi، نويسنده , , Maria Luisa and Furmaniak، نويسنده , , Jadwiga and Bini، نويسنده , , Vittorio and Dotta، نويسنده , , Francesco and Eisenbarth، نويسنده , , George S. and Rees Smith، نويسنده , , Bernard and Betterle، نويسنده , , Corrado، نويسنده ,
Abstract :
21-hydroxylase autoantibodies (21OHAb) are the gold standard immune marker to identify patients with clinical or subclinical autoimmune Addisonʹs disease (AAD). No assessment of interlaboratory concordance has been made for 21OHAb measurement. Serum samples from 267 patients with primary adrenal insufficiency and from 83 healthy control subjects were distributed to four independent laboratories that determined presence and titer of 21OHAb, by using radiobinding assays with either in vitro translated 35S-radiolabelled or 125I-radiolabelled autoantigen. Cohenʹs κ of inter-rater agreement ranged from 0.857 to 0.983, showing a very good concordance of the positive/negative score among the four laboratories. Passing–Bablok regression showed a good agreement of 21OHAb titers arranged by ranks, but important discrepancies emerged at the Bland–Altman plot, as the repeatability coefficient was much higher than the laboratory cut-offs, which indicates that results from different laboratories cannot be used interchangeably. A standardization international program for 21OHAb measurement is strongly needed.
Keywords :
Autoimmune Addisonיs disease , radioimmunoassay , Standardization , autoimmune polyendocrine syndrome , Adrenal insufficiency